• OPEN AN ACCOUNT
Indian Indices
Sensex
85,319.92 644.84
( 0.76%)
Global Indices
Nasdaq
48,381.01 -101.93
(-0.21%)
Dow Jones
6,916.41 -10.33
(-0.15%)
Hang Seng
50,384.39 -142.53
(-0.28%)
Nikkei 225
9,948.02 81.49
(0.83%)
Forex
USD-INR
89.89 0.08
(0.09%)
EUR-INR
105.79 0.08
(0.08%)
GBP-INR
121.32 0.14
(0.12%)
JPY-INR
0.58 0.00
(0.34%)

EQUITY - MARKET SCREENER

Jyoti Structures Ltd
Industry :  Transmisson Line Towers / Equipment
BSE Code
ISIN Demat
Book Value()
513250
INE197A01024
4.4608098
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
JYOTISTRUC
25.05
1106.35
EPS(TTM)
Face Value()
Div & Yield %
0.37
2
0
 

Marksans Pharma’s arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets
Nov 19,2025

The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2 mg, marketed by Kenvue Brands LLC (NDA - 019860).

Loperamide Hydrochloride is an anti-diarrheal medication used to manage symptoms of acute and chronic diarrhea, strengthening Marksans Pharma’s portfolio in the US generic pharmaceutical market.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company’s consolidated net profit rose 1.6% to Rs 98.25 crore on 12.2% jump in revenue from operations to Rs 720.41 crore in Q2 FY26 over Q2 FY25.

Shares of Marksans Pharma fell 1.46% to Rs 189.50 on the BSE.